JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

MacroGenics Inc

Chiusa

SettoreSettore sanitario

1.7 4.29

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.57

Massimo

1.7

Metriche Chiave

By Trading Economics

Entrata

-26M

-41M

Vendite

-4.5M

13M

Margine di Profitto

-311.067

Dipendenti

341

EBITDA

-27M

-39M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+189.63% upside

Dividendi

By Dow Jones

Utili prossimi

11 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-50M

103M

Apertura precedente

-2.59

Chiusura precedente

1.7

Notizie sul Sentiment di mercato

By Acuity

50%

50%

176 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 ago 2025, 23:11 UTC

Utili

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 ago 2025, 22:45 UTC

Utili

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 ago 2025, 22:39 UTC

Utili

Great-West Lifeco Logs Lower 2Q Profit

5 ago 2025, 21:32 UTC

Utili

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 ago 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 ago 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 ago 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 ago 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 ago 2025, 23:48 UTC

Discorsi di Mercato

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 ago 2025, 23:40 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 ago 2025, 23:19 UTC

Discorsi di Mercato

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 ago 2025, 23:03 UTC

Discorsi di Mercato
Utili

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 ago 2025, 22:22 UTC

Utili

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 ago 2025, 22:21 UTC

Utili

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 ago 2025, 22:20 UTC

Utili

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 ago 2025, 22:18 UTC

Utili

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 ago 2025, 22:17 UTC

Utili

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 ago 2025, 22:17 UTC

Utili

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 ago 2025, 22:16 UTC

Utili

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 ago 2025, 22:16 UTC

Utili

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 ago 2025, 22:15 UTC

Utili

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 ago 2025, 22:13 UTC

Utili

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 ago 2025, 22:13 UTC

Utili

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 ago 2025, 22:12 UTC

Utili

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 ago 2025, 22:12 UTC

Utili

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 ago 2025, 21:58 UTC

Utili

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 ago 2025, 21:30 UTC

Utili

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 ago 2025, 21:26 UTC

Utili

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 ago 2025, 21:23 UTC

Utili

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 ago 2025, 21:17 UTC

Utili

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

189.63% in crescita

Previsioni per 12 mesi

Media 4.75 USD  189.63%

Alto 8 USD

Basso 3 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

6 ratings

2

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.47 / 1.64Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

176 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.